

Chemiluminescence Immunoassay Market by Product (Instrument, Consumable), Technology (Chemiluminescence Enzyme, Microparticle Chemiluminescence), Sample (Blood, Urine), Application (Infectious Disease, Oncology), End User - Global Forecast to 2028

<https://marketpublishers.com/r/C92BBC3286BFEN.html>

Date: July 2023

Pages: 276

Price: US\$ 4,950.00 (Single User License)

ID: C92BBC3286BFEN

Abstracts

The chemiluminescence immunoassay market is valued at an estimated USD 13.2 billion in 2023 and is projected to reach USD 19.0 billion by 2028 at a CAGR of 7.5% during the forecast period. Diseases such as HIV/AIDS, hepatitis, respiratory infections and sexually transmitted infections, require an accurate and timely diagnosis for effective treatment and control. Chemiluminescence immunoassay plays a major role in the diagnosis and monitoring of these infectious diseases, driving the growth of the market in this area.

“Blood samples segment is projected to witness highest growth rate in the chemiluminescence immunoassay market, by sample type, during the forecast period”

The chemiluminescence immunoassay market is segmented into blood, urine, saliva, and other sample types. The blood segment in chemiluminescence immunoassay is experiencing significant growth, primarily driven by the increasing number of blood donations and the rising incidence of chronic and infectious diseases also support the growth of the blood samples segment. According to the WHO, in 2020, over 118.5 million blood donations were collected worldwide. The WHO recommends testing all donated blood for infections before use, especially syphilis, HIV, malaria, HBV, and hepatitis B and C.

“Oncology testing segment is projected to register highest growth rate in the chemiluminescence immunoassay market, by application, during the forecast period”

The global chemiluminescence immunoassay market is bifurcated into infectious diseases, endocrinology, oncology, bone & mineral disorders, cardiology, blood screening, autoimmune disorders, allergy diagnostics, toxicology, newborn screening, therapeutic drug monitoring, respiratory, neurology, metabolic disorders, gastroenterology, and other applications. Oncology testing segment is expected to grow at the highest rate within the chemiluminescence immunoassay market. The surge in demand for oncology testing is attributed to various factors such as rise in the incidence of cancer, increasing emphasis on the need for early detection and treatment of cancer, along with measures to increase cancer screening measures.

“Asia Pacific: The fastest-growing region chemiluminescence immunoassay market”

The global chemiluminescence immunoassay market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is projected to register the highest CAGR during the forecast period. Emerging countries in Asia Pacific such as China and India have been investing in developing their healthcare infrastructure, coupled with the presence of large target population. These factors are expected to provide significant growth opportunities for chemiluminescence immunoassay companies operating in this region.

The break-up of the profile of primary participants in the chemiluminescence immunoassay market:

By Company Type: Tier 1 - 28%, Tier 2 - 41%, and Tier 3 – 31%

By Designation: C-level - 30%, D-level - 34%, and Others - 36%

By Region: North America - 37%, Europe - 28%, Asia Pacific - 20%, Rest of the World- 15%

The key players in this market are F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), Siemens Healthineers AG (Germany), DiaSorin S.p.A. (Italy), Abbott Laboratories (US), Shenzhen Mindray Bio-medical Electronics Co., Ltd. (China), Sysmex Corporation (Japan), Diatron (Hungary), Getein Biotech, Inc. (China), Werfen (Spain), QuidelOrtho Corporation (US), EUROIMMUN (Germany), Merck KGaA

(Germany), Tosoh Corporation (Japan), Trivitron Healthcare (India), Abnova Corporation (Taiwan), Elabscience (US), Maccura Biotechnology Co., Ltd. (China), Autobio Diagnostics Co., Ltd. (China), Jiangsu Zecen Biotech Co., Ltd (China), Rayto Life and Analytical Sciences Co., Ltd. (China), Daan Gene Co., Ltd. (China), DYNEX TECHNOLOGIES, Inc. (US), Zybio, Inc. (China), Wiener Laboratorios SAIC (Argentina), Tianjin Era Biology Technology Co., Ltd. (China).

Research Coverage:

This research report categorizes the chemiluminescence immunoassay market by product (consumables and instruments), technology (Chemiluminescence Enzyme Technology (CLEIA), Electrochemiluminescence immunoassay (ECLI), and Microparticle Chemiluminescence Immunoassay), sample type (blood, urine, saliva, and other sample types), application (infectious diseases, endocrinology, oncology, bone & mineral disorders, cardiology, blood screening, autoimmune disorders, allergy diagnostics, toxicology, newborn screening, therapeutic drug monitoring, respiratory, neurology, metabolic disorders, gastroenterology, and other applications), end user (hospitals, clinical laboratories, pharmaceuticals & biotechnology companies and contract research organizations, and other end users), and region (North America, Europe, Asia Pacific, and Rest of the World). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the chemiluminescence immunoassay market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; acquisitions, agreements, new product launches and approvals, and recent developments associated with the chemiluminescence immunoassay market. Competitive analysis of upcoming startups in the chemiluminescence immunoassay market ecosystem is covered in this report.

Reasons to buy this report:

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall chemiluminescence immunoassay market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.

The report provides insights on the following pointers:

Analysis of key drivers (increasing incidences of chronic and infectious diseases, advances in improving the CLIA technologies, rising demand for point-of-care testing (POCT), growth of biotechnology and biopharmaceutical industries, growing geriatric population, and shift towards personalized medicine), restraints (high cost of CLIA systems and reagents and cross-reactivity and interference), opportunities (high growth prospects in emerging countries and collaborations and partnerships), and challenges (unfavorable reimbursement scenario and lack of skilled professionals) influencing the growth of the chemiluminescence immunoassay market

Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the chemiluminescence immunoassay market.

Market Development: Comprehensive information about lucrative markets – the report analyses the chemiluminescence immunoassay market across varied regions.

Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the chemiluminescence immunoassay market

Competitive Assessment: In-depth assessment of market shares, growth strategies and service offerings of leading players like F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), Seimens Healthineers AG (Germany), Abbott Laboratories (US), and DiaSorin S.p.A.(Italy), among others in the chemiluminescence immunoassay market strategies.

Contents

1 INTRODUCTION

1.1 STUDY OBJECTIVES

1.2 MARKET DEFINITION

1.2.1 INCLUSIONS AND EXCLUSIONS

1.3 MARKET SCOPE

1.3.1 MARKETS COVERED

FIGURE 1 CHEMILUMINESCENCE IMMUNOASSAY MARKET SEGMENTATION

1.3.2 GEOGRAPHICAL SCOPE

1.3.3 YEARS CONSIDERED

1.4 CURRENCY CONSIDERED

1.5 STAKEHOLDERS

2 RESEARCH METHODOLOGY

2.1 RESEARCH APPROACH

FIGURE 2 RESEARCH DESIGN

2.1.1 SECONDARY DATA

2.1.1.1 Key data from secondary sources

2.1.2 PRIMARY DATA

2.1.2.1 Primary sources

2.1.2.2 Key data from primary sources

2.1.2.3 Key industry insights

FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY AND DEMAND SIDE PARTICIPANTS

FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION

2.2 MARKET SIZE ESTIMATION

FIGURE 5 REVENUE SHARE ANALYSIS ILLUSTRATION

FIGURE 6 MARKET ESTIMATION FROM IVD MARKET

FIGURE 7 MARKET ESTIMATION FROM IMMUNOASSAY MARKET

FIGURE 8 CAGR PROJECTIONS: SUPPLY SIDE ANALYSIS OF CHEMILUMINESCENCE IMMUNOASSAY MARKET

FIGURE 9 TOP-DOWN APPROACH

2.3 MARKET BREAKDOWN AND DATA TRIANGULATION

FIGURE 10 DATA TRIANGULATION METHODOLOGY

2.4 MARKET SHARE ANALYSIS

2.5 STUDY ASSUMPTIONS

2.6 RESEARCH LIMITATIONS

2.7 RISK ASSESSMENT

TABLE 1 RISK ASSESSMENT: CHEMILUMINESCENCE IMMUNOASSAY MARKET

2.8 GROWTH RATE ASSUMPTIONS

2.9 IMPACT OF RECESSION ON CHEMILUMINESCENCE IMMUNOASSAY MARKET

3 EXECUTIVE SUMMARY

FIGURE 11 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2023 VS. 2028 (USD BILLION)

FIGURE 12 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD BILLION)

FIGURE 13 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2023 VS. 2028 (USD BILLION)

FIGURE 14 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2023 VS. 2028 (USD BILLION)

FIGURE 15 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2023 VS. 2028 (USD BILLION)

FIGURE 16 GEOGRAPHICAL SNAPSHOT OF CHEMILUMINESCENCE IMMUNOASSAY MARKET

4 PREMIUM INSIGHTS

4.1 CHEMILUMINESCENCE IMMUNOASSAY MARKET OVERVIEW

FIGURE 17 INCREASING INCIDENCE OF DISEASES AND TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET

4.2 NORTH AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT (2022)

FIGURE 18 CONSUMABLES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022

4.3 GEOGRAPHICAL GROWTH OPPORTUNITIES IN CHEMILUMINESCENCE IMMUNOASSAY MARKET

FIGURE 19 CHINA AND INDIA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD

4.4 CHEMILUMINESCENCE IMMUNOASSAY MARKET: REGIONAL MIX

FIGURE 20 ASIA PACIFIC TO WITNESS HIGHEST GROWTH RATE DURING STUDY PERIOD

4.5 CHEMILUMINESCENCE IMMUNOASSAY MARKET: DEVELOPED VS.

DEVELOPING MARKETS

FIGURE 21 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH DURING STUDY PERIOD

5 MARKET OVERVIEW

5.1 INTRODUCTION

5.2 MARKET DYNAMICS

FIGURE 22 CHEMILUMINESCENCE IMMUNOASSAY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES

5.2.1 DRIVERS

5.2.1.1 Increasing incidences of chronic and infectious diseases globally

FIGURE 23 INCREASING INCIDENCES OF DIABETES (GLOBAL)

FIGURE 24 NUMBER OF PEOPLE WITH CHRONIC CONDITIONS IN US, 1995–2030 (MILLION INDIVIDUALS)

5.2.1.2 Advancements in improving chemiluminescence immunoassay technologies in recent years

5.2.1.3 Growth of biotechnology and biopharmaceutical industries

5.2.1.4 Rapid increase in geriatric population globally

FIGURE 25 GLOBAL GERIATRIC POPULATION, BY REGION, 2019 VS. 2050 (MILLION)

5.2.1.5 Shift toward personalized medicines and individualized treatment decisions

5.2.2 RESTRAINTS

5.2.2.1 High cost of chemiluminescence systems and reagents

5.2.2.2 Lack of regular quality control procedures for monitoring and detecting cross-reactivity and interference

5.2.3 OPPORTUNITIES

5.2.3.1 High growth prospects for players in emerging economies

5.2.3.2 Increasing number of collaborations and partnerships

5.2.4 CHALLENGES

5.2.4.1 Unfavorable reimbursement scenario and budgetary constraints in healthcare systems

5.2.4.2 Lack of skilled professionals and aging workforce

5.3 VALUE CHAIN ANALYSIS

FIGURE 26 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES

5.4 SUPPLY CHAIN ANALYSIS

FIGURE 27 DIRECT DISTRIBUTION TO BE PREFERRED STRATEGY FOR PROMINENT COMPANIES

5.5 PORTER'S FIVE FORCES ANALYSIS

TABLE 2 HIGH CONSOLIDATION IN MARKET TO RESTRICT ENTRY OF NEW PLAYERS

5.5.1 DEGREE OF COMPETITION

5.5.2 BARGAINING POWER OF SUPPLIERS

5.5.3 BARGAINING POWER OF BUYERS

5.5.4 THREAT OF SUBSTITUTES

5.5.5 THREAT OF NEW ENTRANTS

5.6 KEY STAKEHOLDERS AND BUYING CRITERIA

5.6.1 KEY STAKEHOLDERS IN BUYING PROCESS

FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS

TABLE 3 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS

5.6.2 BUYING CRITERIA

FIGURE 29 KEY BUYING CRITERIA FOR MAJOR END USERS

TABLE 4 KEY BUYING CRITERIA, BY END USER

5.7 REGULATORY LANDSCAPE

5.7.1 US

TABLE 5 US: CLASSIFICATION OF IMMUNOASSAY PRODUCTS

FIGURE 30 US: REGULATORY PROCESS FOR IVD DEVICES

5.7.2 CANADA

FIGURE 31 CANADA: REGULATORY PROCESS FOR IVD DEVICES

5.7.3 EUROPE

TABLE 6 EUROPE: CLASSIFICATION OF IVD DEVICES

5.7.4 JAPAN

FIGURE 32 JAPAN: REGULATORY PROCESS FOR IVD DEVICES

TABLE 7 JAPAN: CLASSIFICATION OF IVD REAGENTS

TABLE 8 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS

5.7.5 CHINA

TABLE 9 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS

5.7.6 INDIA

FIGURE 33 INDIA: REGULATORY PROCESS FOR IVD DEVICES

5.7.7 INDONESIA

TABLE 10 INDONESIA: REGISTRATION PROCESS FOR IVD DEVICES

5.7.8 RUSSIA

TABLE 11 RUSSIA: CLASSIFICATION OF IVD DEVICES

5.7.9 SAUDI ARABIA

TABLE 12 SAUDI ARABIA: TIME, COST, AND COMPLEXITY OF REGISTRATION

PROCESS

5.7.10 MEXICO

FIGURE 34 MEXICO: REGULATORY PROCESS FOR IVD DEVICES

TABLE 13 MEXICO: TIME, COST, AND COMPLEXITY OF REGISTRATION

PROCESS

5.7.11 BRAZIL

FIGURE 35 BRAZIL: REGULATORY PROCESS FOR IVD DEVICES

5.7.12 SOUTH KOREA

TABLE 14 SOUTH KOREA: TIME, COST, AND COMPLEXITY OF REGISTRATION

PROCESS

5.7.13 MIDDLE EAST

5.7.14 AFRICA

5.8 TECHNOLOGY ANALYSIS

TABLE 15 RECENT PRODUCT LAUNCHES WITH ADVANCED TECHNOLOGIES IN CHEMILUMINESCENCE IMMUNOASSAY MARKET

5.9 TRADE ANALYSIS

5.9.1 TRADE ANALYSIS FOR CHEMILUMINESCENCE IMMUNOASSAYS

TABLE 16 IMPORT DATA FOR HS CODE 902780, BY COUNTRY, 2018–2022 (USD MILLION)

TABLE 17 EXPORT DATA FOR HS CODE 902780, BY COUNTRY, 2018–2022 (USD MILLION)

5.10 ECOSYSTEM MAPPING

FIGURE 36 ECOSYSTEM MAPPING OF CHEMILUMINESCENCE IMMUNOASSAY MARKET

5.10.1 ROLE IN ECOSYSTEM

5.10.2 KEY PLAYERS OPERATING IN CHEMILUMINESCENCE IMMUNOASSAY MARKET

5.11 PATENT ANALYSIS

5.12 KEY CONFERENCES AND EVENTS IN 2023–2024

TABLE 18 LIST OF CONFERENCES AND EVENTS IN 2023–2024

5.13 PRICING ANALYSIS

5.13.1 AVERAGE SELLING PRICE, BY APPLICATION (KEY PLAYERS)

TABLE 19 PRICE RANGE OFFERED BY KEY PLAYERS, BY APPLICATION (USD)

5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES

6 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT

6.1 INTRODUCTION

TABLE 20 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT,

2021–2028 (USD MILLION)

6.2 CONSUMABLES

6.2.1 CONSUMABLES TO ACCOUNT FOR LARGEST SHARE OF CHEMILUMINESCENCE IMMUNOASSAY MARKET DURING STUDY PERIOD
TABLE 21 LIST OF CHEMILUMINESCENCE IMMUNOASSAY CONSUMABLES AVAILABLE

TABLE 22 CHEMILUMINESCENCE IMMUNOASSAY MARKET FOR CONSUMABLES, BY REGION, 2021–2028 (USD MILLION)

6.3 INSTRUMENTS

6.3.1 INCREASING ADVANCES WITH HIGH-THROUGHPUT CAPACITIES AND GROWING AUTOMATION TRENDS TO DRIVE MARKET
TABLE 23 LIST OF CHEMILUMINESCENCE IMMUNOASSAY INSTRUMENTS AVAILABLE

TABLE 24 CHEMILUMINESCENCE IMMUNOASSAY MARKET FOR INSTRUMENTS, BY REGION, 2021–2028 (USD MILLION)

7 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY

7.1 INTRODUCTION

TABLE 25 CHEMILUMINESCENCE IMMUNOASSAYS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)

7.2 CHEMILUMINESCENCE ENZYME

7.2.1 HIGH RELIABILITY OF BLOOD TESTS IN CLINICAL DIAGNOSTICS AND PHARMACEUTICAL RESEARCH TO DRIVE MARKET
TABLE 26 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR CHEMILUMINESCENCE ENZYME, BY REGION, 2021–2028 (USD MILLION)

7.3 ELECTROCHEMILUMINESCENCE IMMUNOASSAY

7.3.1 INCREASED GENERATION OF EXCITED STATES THROUGH BETTER ELECTRODE VARIATION TO DRIVE MARKET
TABLE 27 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR ELECTROCHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2021–2028 (USD MILLION)

7.4 MICROPARTICLE CHEMILUMINESCENCE IMMUNOASSAY

7.4.1 HIGHER COSTS AND GREATER CHANCES OF CROSS-REACTIVITY DUE TO MULTIPLEXING TO LIMIT MARKET
TABLE 28 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR MICROPARTICLE CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2021–2028 (USD MILLION)

8 CHEMILUMINESCENCE IMMUNOASSAYS MARKET, BY SAMPLE TYPE

8.1 INTRODUCTION

TABLE 29 CHEMILUMINESCENCE IMMUNOASSAYS MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)

8.2 BLOOD

8.2.1 HIGH RELIABILITY OF BLOOD TESTS FOR IMMUNOASSAY DIAGNOSTIC PROCEDURES AND HEALTH SCREENING TO DRIVE MARKET

TABLE 30 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR BLOOD, BY REGION, 2021–2028 (USD MILLION)

8.3 URINE

8.3.1 INCREASING USE IN LAW ENFORCEMENT AND DRUG TESTING CENTERS TO DRIVE MARKET

TABLE 31 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR URINE, BY REGION, 2021–2028 (USD MILLION)

8.4 SALIVA

8.4.1 CONVENIENCE AND EASY TESTING OF BIOLOGICALLY ACTIVE PARTS OF HORMONES TO DRIVE MARKET

TABLE 32 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR SALIVA, BY REGION, 2021–2028 (USD MILLION)

8.5 OTHER SAMPLE TYPES

TABLE 33 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR OTHER SAMPLE TYPES, BY REGION, 2021–2028 (USD MILLION)

9 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION

9.1 INTRODUCTION

TABLE 34 CHEMILUMINESCENCE IMMUNOASSAYS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

9.2 INFECTIOUS DISEASES

9.2.1 RISING PREVALENCE OF INFECTIOUS DISEASES GLOBALLY AMONG ALL AGE GROUPS TO DRIVE MARKET

TABLE 35 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021–2028 (USD MILLION)

9.3 ENDOCRINOLOGY

9.3.1 RISING INCIDENCES OF DIABETES GLOBALLY TO DRIVE MARKET

TABLE 36 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR ENDOCRINOLOGY, BY REGION, 2021–2028 (USD MILLION)

9.4 ONCOLOGY

9.4.1 RISING BURDEN OF CANCER AND EMPHASIS ON EARLY DISEASE DIAGNOSIS TO DRIVE MARKET

TABLE 37 INCREASING INCIDENCE OF CANCER, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION)

TABLE 38 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR ONCOLOGY, BY REGION, 2021–2028 (USD MILLION)

9.5 CARDIOLOGY

9.5.1 HIGH BURDEN OF CARDIOVASCULAR DISEASES AMONG ALL AGE GROUPS TO DRIVE MARKET

TABLE 39 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR CARDIOLOGY, BY REGION, 2021–2028 (USD MILLION)

9.6 ALLERGY DIAGNOSTICS

9.6.1 GROWING PREVALENCE OF ALLERGIES TO REGISTER INCREASED DEMAND FOR CHEMILUMINESCENCE IMMUNOASSAYS

TABLE 40 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR ALLERGY DIAGNOSTICS, BY REGION, 2021–2028 (USD MILLION)

9.7 BLOOD SCREENING

9.7.1 RISING VOLUME OF BLOOD DONATIONS AND INCREASING INCIDENCES OF BLOOD-RELATED DISORDERS TO DRIVE MARKET

TABLE 41 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR BLOOD SCREENING, BY REGION, 2021–2028 (USD MILLION)

9.8 AUTOIMMUNE DISORDERS

9.8.1 GROWING PREVALENCE OF AUTOIMMUNE DISORDERS AND RISING ECONOMIC BURDEN OF DISEASE MANAGEMENT TO DRIVE MARKET

TABLE 42 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR AUTOIMMUNE DISORDERS, BY REGION, 2021–2028 (USD MILLION)

9.9 BONE & MINERAL DISORDERS

9.9.1 HIGH DISORDER PREVALENCE TO INDICATE STRONG GROWTH OPPORTUNITIES FOR IMMUNOASSAYS

TABLE 43 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR BONE & MINERAL DISORDERS, BY REGION, 2021–2028 (USD MILLION)

9.10 TOXICOLOGY

9.10.1 INCREASED DRUG-OF-ABUSE TESTING AND HIGHER ILLICIT DRUG CONSUMPTION TO DRIVE MARKET

TABLE 44 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR TOXICOLOGY, BY REGION, 2021–2028 (USD MILLION)

9.11 NEWBORN SCREENING

9.11.1 CHEMILUMINESCENCE IMMUNOASSAYS TO BE ROUTINELY USED AS FIRST-TIER NEWBORN SCREENING PROTOCOL

TABLE 45 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR NEWBORN SCREENING, BY REGION, 2021–2028 (USD MILLION)

9.12 THERAPEUTIC DRUG MONITORING

9.12.1 RAPID DETECTION TIME AND GOOD SPECIFICITY TO DRIVE MARKET

TABLE 46 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR THERAPEUTIC DRUG MONITORING, BY REGION, 2021–2028 (USD MILLION)

9.13 METABOLIC DISORDERS

9.13.1 RISING PREVALENCE OF METABOLIC DISORDERS TO DRIVE MARKET

FIGURE 37 GLOBAL INCIDENCE OF DIABETES

TABLE 47 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR METABOLIC DISORDERS, BY REGION, 2021–2028 (USD MILLION)

9.14 GASTROENTEROLOGY

9.14.1 INCREASING INCIDENCE OF GASTROINTESTINAL TRACT INFECTIONS AND SERIOUS GASTRIC DISEASES TO DRIVE MARKET

TABLE 48 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR GASTROENTEROLOGY, BY REGION, 2021–2028 (USD MILLION)

9.15 NEUROLOGY

9.15.1 EFFECTIVE DETECTION, MONITORING, AND MANAGEMENT OF NEUROLOGICAL DISORDERS TO DRIVE SEGMENT

TABLE 49 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR NEUROLOGY, BY REGION, 2021–2028 (USD MILLION)

9.16 RESPIRATORY

9.16.1 EASY DETECTION AND DIAGNOSIS OF RESPIRATORY DISEASES TO DRIVE MARKET

TABLE 50 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR RESPIRATORY, BY REGION, 2021–2028 (USD MILLION)

9.17 OTHER APPLICATIONS

TABLE 51 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR OTHER APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)

10 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER

10.1 INTRODUCTION

TABLE 52 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)

10.2 HOSPITALS

10.2.1 GROWING PATIENT POPULATION AND TESTING VOLUMES TO DRIVE MARKET

TABLE 53 CHEMILUMINESCENCE IMMUNOASSAY MARKET FOR HOSPITALS, BY

REGION, 2021–2028 (USD MILLION)

10.3 CLINICAL LABORATORIES

10.3.1 RISING CLINICAL TEST VOLUMES AND REQUIREMENTS TO DRIVE SEGMENT

TABLE 54 CHEMILUMINESCENCE IMMUNOASSAY MARKET FOR CLINICAL LABORATORIES, BY REGION, 2021–2028 (USD MILLION)

10.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CONTRACT RESEARCH ORGANIZATIONS

10.4.1 RISING DRUG DISCOVERIES AND CLINICAL STUDIES TO DRIVE MARKET
TABLE 55 CHEMILUMINESCENCE IMMUNOASSAY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2021–2028 (USD MILLION)

10.5 OTHER END USERS

TABLE 56 CHEMILUMINESCENCE IMMUNOASSAY MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION)

11 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY REGION

11.1 INTRODUCTION

TABLE 57 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY REGION, 2021–2028 (USD MILLION)

11.2 NORTH AMERICA

FIGURE 38 NORTH AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET SNAPSHOT

TABLE 58 NORTH AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 59 NORTH AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

TABLE 60 NORTH AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)

TABLE 61 NORTH AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)

TABLE 62 NORTH AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 63 NORTH AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)

11.2.1 IMPACT OF ECONOMIC RECESSION ON NORTH AMERICA

11.2.2 US

11.2.2.1 US to hold largest share in North American chemiluminescence

immunoassay market during forecast period

TABLE 64 US: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

TABLE 65 US: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)

TABLE 66 US: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)

TABLE 67 US: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 68 US: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)

11.2.3 CANADA

11.2.3.1 Rising government initiatives and funding for early disease diagnosis to drive market

TABLE 69 CANADA: ESTIMATED PREVALENCE OF DIABETES

TABLE 70 CANADA: MACROECONOMIC INDICATORS

TABLE 71 CANADA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

TABLE 72 CANADA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)

TABLE 73 CANADA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)

TABLE 74 CANADA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 75 CANADA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)

11.3 EUROPE

TABLE 76 EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 77 EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

TABLE 78 EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)

TABLE 79 EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)

TABLE 80 EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 81 EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)

11.3.1 IMPACT OF ECONOMIC RECESSION ON EUROPE

11.3.2 GERMANY

11.3.2.1 Growing investments in clinical diagnostics research and increasing government spending on healthcare to drive market

TABLE 82 GERMANY: MACROECONOMIC INDICATORS

TABLE 83 GERMANY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

TABLE 84 GERMANY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)

TABLE 85 GERMANY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)

TABLE 86 GERMANY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 87 GERMANY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)

11.3.3 FRANCE

11.3.3.1 Favorable reimbursement policies and increased investments in diagnostics to drive market

TABLE 88 FRANCE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

TABLE 89 FRANCE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)

TABLE 90 FRANCE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)

TABLE 91 FRANCE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 92 FRANCE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)

11.3.4 UK

11.3.4.1 Increasing number of accredited clinical laboratories and growing accessibility to IVD tests to drive market

TABLE 93 UK: MACROECONOMIC INDICATORS

TABLE 94 UK: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

TABLE 95 UK: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)

TABLE 96 UK: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)

TABLE 97 UK: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY

APPLICATION, 2021–2028 (USD MILLION)

TABLE 98 UK: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)

11.3.5 ITALY

11.3.5.1 Growing geriatric population and increasing support for research to drive market

TABLE 99 ITALY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

TABLE 100 ITALY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)

TABLE 101 ITALY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)

TABLE 102 ITALY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 103 ITALY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)

11.3.6 SPAIN

11.3.6.1 Rising adoption of technologically advanced immunoassay systems to drive market

TABLE 104 SPAIN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

TABLE 105 SPAIN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)

TABLE 106 SPAIN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)

TABLE 107 SPAIN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 108 SPAIN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)

11.3.7 REST OF EUROPE

TABLE 109 REST OF EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

TABLE 110 REST OF EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)

TABLE 111 REST OF EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)

TABLE 112 REST OF EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 113 REST OF EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET,

BY END USER, 2021–2028 (USD MILLION)

11.4 ASIA PACIFIC

FIGURE 39 ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET
SNAPSHOT

TABLE 114 ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY
COUNTRY, 2021–2028 (USD MILLION)

TABLE 115 ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY
PRODUCT, 2021–2028 (USD MILLION)

TABLE 116 ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY
TECHNOLOGY, 2021–2028 (USD MILLION)

TABLE 117 ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY
SAMPLE TYPE, 2021–2028 (USD MILLION)

TABLE 118 ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY
APPLICATION, 2021–2028 (USD MILLION)

TABLE 119 ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY
END USER, 2021–2028 (USD MILLION)

11.4.1 IMPACT OF ECONOMIC RECESSION ON ASIA PACIFIC

11.4.2 JAPAN

11.4.2.1 Growing investments in clinical diagnostics research to drive market

TABLE 120 JAPAN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY
PRODUCT, 2021–2028 (USD MILLION)

TABLE 121 JAPAN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY
TECHNOLOGY, 2021–2028 (USD MILLION)

TABLE 122 JAPAN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE
TYPE, 2021–2028 (USD MILLION)

TABLE 123 JAPAN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY
APPLICATION, 2021–2028 (USD MILLION)

TABLE 124 JAPAN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END
USER, 2021–2028 (USD MILLION)

11.4.3 CHINA

11.4.3.1 China to register highest growth rate in Asia Pacific chemiluminescence
immunoassay market during study period

TABLE 125 CHINA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY
PRODUCT, 2021–2028 (USD MILLION)

TABLE 126 CHINA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY
TECHNOLOGY, 2021–2028 (USD MILLION)

TABLE 127 CHINA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE
TYPE, 2021–2028 (USD MILLION)

TABLE 128 CHINA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY

APPLICATION, 2021–2028 (USD MILLION)

TABLE 129 CHINA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)

11.4.4 INDIA

11.4.4.1 Growing medical tourism and healthcare infrastructure to drive market
TABLE 130 INDIA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

TABLE 131 INDIA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)

TABLE 132 INDIA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)

TABLE 133 INDIA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 134 INDIA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)

11.4.5 SOUTH KOREA

11.4.5.1 Rising healthcare spending for innovative IVD technologies to drive market
TABLE 135 SOUTH KOREA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

TABLE 136 SOUTH KOREA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)

TABLE 137 SOUTH KOREA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)

TABLE 138 SOUTH KOREA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 139 SOUTH KOREA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)

11.4.6 REST OF ASIA PACIFIC

TABLE 140 REST OF ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

TABLE 141 REST OF ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)

TABLE 142 REST OF ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)

TABLE 143 REST OF ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 144 REST OF ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)

11.5 REST OF THE WORLD

TABLE 145 REST OF THE WORLD: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY REGION, 2021–2028 (USD MILLION)

TABLE 146 REST OF THE WORLD: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

TABLE 147 REST OF THE WORLD: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)

TABLE 148 REST OF THE WORLD: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)

TABLE 149 REST OF THE WORLD: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 150 REST OF THE WORLD: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)

11.5.1 IMPACT OF ECONOMIC RECESSION ON REST OF THE WORLD

11.5.2 LATIN AMERICA

11.5.2.1 Rising incidence of infectious diseases and increasing geriatric population to drive market

TABLE 151 LATIN AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

TABLE 152 LATIN AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)

TABLE 153 LATIN AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)

TABLE 154 LATIN AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 155 LATIN AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)

11.5.3 MIDDLE EAST & AFRICA

11.5.3.1 Lack of skilled laboratory personnel and unfavorable reimbursement policies to limit market

TABLE 156 MIDDLE EAST & AFRICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)

TABLE 157 MIDDLE EAST & AFRICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)

TABLE 158 MIDDLE EAST & AFRICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)

TABLE 159 MIDDLE EAST & AFRICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 160 MIDDLE EAST & AFRICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION)

12 COMPETITIVE LANDSCAPE

12.1 OVERVIEW

12.2 STRATEGIES ADOPTED BY KEY PLAYERS

TABLE 161 OVERVIEW OF STRATEGIES ADOPTED BY KEY MANUFACTURERS OF CHEMILUMINESCENCE IMMUNOASSAY PRODUCTS

12.3 REVENUE ANALYSIS OF TOP MARKET PLAYERS

FIGURE 40 REVENUE ANALYSIS OF TOP MARKET PLAYERS IN CHEMILUMINESCENCE IMMUNOASSAY MARKET

12.4 MARKET SHARE ANALYSIS

TABLE 162 CHEMILUMINESCENCE IMMUNOASSAY MARKET: DEGREE OF COMPETITION

FIGURE 41 CHEMILUMINESCENCE IMMUNOASSAY MARKET SHARE, BY KEY PLAYER (2022)

12.5 COMPANY EVALUATION MATRIX FOR KEY PLAYERS

12.5.1 STARS

12.5.2 EMERGING LEADERS

12.5.3 PERVASIVE PLAYERS

12.5.4 PARTICIPANTS

FIGURE 42 CHEMILUMINESCENCE IMMUNOASSAY MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS

12.6 COMPANY EVALUATION MATRIX FOR SMES/START-UPS

12.6.1 PROGRESSIVE COMPANIES

12.6.2 STARTING BLOCKS

12.6.3 RESPONSIVE COMPANIES

12.6.4 DYNAMIC COMPANIES

FIGURE 43 CHEMILUMINESCENCE IMMUNOASSAY MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES

12.7 COMPETITIVE BENCHMARKING

TABLE 163 CHEMILUMINESCENCE IMMUNOASSAY MARKET: DETAILED LIST OF KEY START-UPS/SMES

12.8 COMPANY FOOTPRINT ANALYSIS

TABLE 164 OVERALL COMPANY FOOTPRINT

TABLE 165 COMPANY PRODUCT FOOTPRINT

TABLE 166 COMPANY REGIONAL FOOTPRINT

12.9 COMPETITIVE SCENARIO

12.9.1 KEY PRODUCT LAUNCHES AND APPROVALS

TABLE 167 CHEMILUMINESCENCE IMMUNOASSAY MARKET: KEY PRODUCT

LAUNCHES AND APPROVALS, 2020–2023

12.9.2 KEY DEALS

TABLE 168 CHEMILUMINESCENCE IMMUNOASSAY MARKET: KEY DEALS, 2020–2023

12.9.3 OTHER KEY DEVELOPMENTS

TABLE 169 CHEMILUMINESCENCE IMMUNOASSAY MARKET: OTHER KEY DEVELOPMENTS, 2020–2023

13 COMPANY PROFILES

13.1 KEY PLAYERS

(Business Overview, Products/Solutions Offered, Recent Developments, SWOT Analysis, Winning Imperatives, Current Focus and Strategies, Threat From Competition, Right to Win)*

13.1.1 F. HOFFMANN-LA ROCHE LTD.

TABLE 170 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW

FIGURE 44 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022)

13.1.2 DANAHER CORPORATION

TABLE 171 DANAHER CORPORATION: COMPANY OVERVIEW

FIGURE 45 DANAHER CORPORATION: COMPANY SNAPSHOT (2022)

13.1.3 SIEMENS HEALTHINEERS AG

TABLE 172 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW

FIGURE 46 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2022)

13.1.4 DIASORIN S.P.A.

TABLE 173 DIASORIN S.P.A.: COMPANY OVERVIEW

FIGURE 47 DIASORIN S.P.A.: COMPANY SNAPSHOT (2022)

13.1.5 ABBOTT LABORATORIES

TABLE 174 ABBOTT LABORATORIES: COMPANY OVERVIEW

FIGURE 48 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2022)

13.1.6 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.

TABLE 175 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: COMPANY OVERVIEW

FIGURE 49 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: COMPANY SNAPSHOT (2021)

13.1.7 SYSMEX CORPORATION

TABLE 176 SYSMEX CORPORATION: COMPANY OVERVIEW

FIGURE 50 SYSMEX CORPORATION: COMPANY SNAPSHOT (2022)

13.1.8 DIATRON

TABLE 177 DIATRON: COMPANY OVERVIEW

FIGURE 51 STRATEC SE: COMPANY SNAPSHOT (2022)

13.1.9 GETEIN BIOTECH, INC.

TABLE 178 GETEIN BIOTECH, INC.: COMPANY OVERVIEW

13.1.10 WERFEN

TABLE 179 WERFEN: COMPANY OVERVIEW

13.1.11 QUIDELORTHO CORPORATION

TABLE 180 QUIDELORTHO CORPORATION: COMPANY OVERVIEW

FIGURE 52 QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2022)

13.1.12 EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG

TABLE 181 EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG: COMPANY OVERVIEW

*Business Overview, Products/Solutions Offered, Recent Developments, SWOT Analysis, Winning Imperatives, Current Focus and Strategies, Threat From Competition, Right to Win might not be captured in case of unlisted companies.

13.2 OTHER PLAYERS

13.2.1 MERCK KGAA

13.2.2 TOSOH CORPORATION (TOSOH BIOSCIENCE)

13.2.3 TRIVITRON HEALTHCARE

13.2.4 ABNOVA CORPORATION

13.2.5 ELABSCIENCE

13.2.6 MACCURA BIOTECHNOLOGY CO., LTD.

13.2.7 AUTOBIO DIAGNOSTICS CO., LTD

13.2.8 JIANGSU ZECEN BIOTECH CO., LTD

13.2.9 RAYTO LIFE AND ANALYTICAL SCIENCES CO., LTD.

13.2.10 DAAN GENE CO., LTD.

13.2.11 DYNEX TECHNOLOGIES, INC.

13.2.12 ZYBIO INC.

13.2.13 WIENER LABORATORIOS SAIC

13.2.14 TIANJIN ERA BIOLOGY TECHNOLOGY CO., LTD.

14 APPENDIX

14.1 DISCUSSION GUIDE

14.2 KNOWLEDGESTORE: MARKETSandMARKETS' SUBSCRIPTION PORTAL

14.3 CUSTOMIZATION OPTIONS

14.4 RELATED REPORTS

14.5 AUTHOR DETAILS

I would like to order

Product name: Chemiluminescence Immunoassay Market by Product (Instrument, Consumable), Technology (Chemiluminescence Enzyme, Microparticle Chemiluminescence), Sample (Blood, Urine), Application (Infectious Disease, Oncology), End User - Global Forecast to 2028

Product link: <https://marketpublishers.com/r/C92BBC3286BFEN.html>

Price: US\$ 4,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C92BBC3286BFEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970